Trials / Conditions / Primary Focal Segmental Glomerulosclerosis
Primary Focal Segmental Glomerulosclerosis
6 registered clinical trials studyying Primary Focal Segmental Glomerulosclerosis — 2 currently recruiting.
| Status | Trial | Sponsor | Phase |
|---|---|---|---|
| Recruiting | Study of WAL0921 in Patients With Glomerular Kidney Diseases NCT06466135 | Walden Biosciences | Phase 2 |
| Not Yet Recruiting | Circulating Factors in Nephrotic Syndrome NCT06315504 | Iain Bressendorff | — |
| Completed | Obinutuzumab in Primary FSGS NCT04983888 | Mayo Clinic | Phase 2 |
| Completed | FIRSTx - A Study of Oral CXA-10 in Primary Focal Segmental Glomerulosclerosis (FSGS) NCT03422510 | Complexa, Inc. | Phase 2 |
| Completed | A Pilot Study to Assess the Efficacy of Rituximab Therapy in Treatment Resistant FSGS NCT01573533 | Mayo Clinic | Phase 2 |
| Completed | A Study of Fresolimumab in Patients With Steroid-Resistant Primary Focal Segmental Glomerulosclerosis (FSGS) NCT01665391 | Genzyme, a Sanofi Company | Phase 2 |